SEC Tracker
Get the app

IRulya Therapeutics IRLA

IRulya Therapeutics (QNCX) reports ownership

Keith R. Fandrick, new insider at QNCX

Form
3
Filed
Importance
Routine
  1. Fandrick Keith R. is Chief Operating Officer
  2. Owns 30,442 shares via stock options
  3. Options expire up to 2036
  4. Stock options valued at $1.81 to $16.81

Written from the Form 3 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when IRulya Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Veru VERU public float $64M, Mar 31, 2025, over 18 months old
  2. Lifevantage LFVN public float $64M, Dec 31, 2025
  3. Whitehawk Therapeutics WHWK public float $65M, Jun 30, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025